Cytokinetics presents positive data on aficamten for hypertrophic cardiomyopathy patients
From GlobeNewswire: 2025-05-18 08:00:00
Cytokinetics, Incorporated shared new data from SEQUOIA-HCM, analyzing the impact of aficamten on patients with obstructive hypertrophic cardiomyopathy (HCM) and non-obstructive HCM at the European Society of Cardiology Heart Failure 2025 Congress. The data showed consistent effects of aficamten on exercise capacity, symptoms, and biomarkers across different baseline symptom severities and geographic regions. Additionally, a real-world analysis revealed disparities in outcomes for females and older patients with non-obstructive HCM. This research sheds light on the potential applications of aficamten in various patient populations with HCM, highlighting the need for personalized treatment approaches. The development program for aficamten is evaluating its potential as a treatment for patients with hypertrophic cardiomyopathy (HCM) to improve exercise capacity and relieve symptoms. Aficamten has received Breakthrough Therapy Designation from the FDA and NMPA. Cytokinetics is a biopharmaceutical company focusing on advancing potential new medicines for cardiac muscle dysfunction, including aficamten, a cardiac myosin inhibitor. HCM is a common inherited cardiovascular disorder affecting approximately 280,000 diagnosed patients in the U.S., with many more undiagnosed. Patients with HCM are at risk of developing complications like atrial fibrillation, stroke, and sudden cardiac death. Cytokinetics announces results from the SEQUOIA-HCM trial for Aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. The study was published in the European Heart Journal in 2025. The drug is a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. According to Symphony Health patient claims data from 2016-2021, clinically diagnosed hypertrophic cardiomyopathy occurs in the United States. Risk factors for sudden cardiac death in hypertrophic cardiomyopathy include age and family history. Cytokinetics is a registered trademark. Contact Diane Weiser for more information.
Read more at GlobeNewswire: Cytokinetics Presents Additional Data Related to Aficamten